Susquehanna International Group’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $358K | Sell |
298,496
-11,695
| -4% | -$14.2K | ﹤0.01% | 10473 |
|
|
2025
Q4 | $305K | Buy |
310,191
+131,264
| +73% | +$158K | ﹤0.01% | 9909 |
|
|
2025
Q3 | $225K | Sell |
178,927
-110,305
| -38% | -$119K | ﹤0.01% | 10726 |
|
|
2025
Q2 | $324K | Buy |
289,232
+111,872
| +63% | +$130K | ﹤0.01% | 10165 |
|
|
2025
Q1 | $140K | Buy |
177,360
+69,946
| +65% | +$85.7K | ﹤0.01% | 11283 |
|
|
2024
Q4 | $177K | Buy |
107,414
+50,653
| +89% | +$128K | ﹤0.01% | 10859 |
|
|
2024
Q3 | $199K | Buy |
56,761
+3,468
| +7% | +$13.5K | ﹤0.01% | 10477 |
|
|
2024
Q2 | $175K | Sell |
53,293
-40,043
| -43% | -$175K | ﹤0.01% | 10533 |
|
|
2024
Q1 | $685K | Sell |
93,336
-59,173
| -39% | -$366K | ﹤0.01% | 7747 |
|
|
2023
Q4 | $570K | Sell |
152,509
-282,623
| -65% | -$667K | ﹤0.01% | 8333 |
|
|
2023
Q3 | $922K | Sell |
435,132
-50,226
| -10% | -$166K | ﹤0.01% | 6803 |
|
|
2023
Q2 | $2.31M | Sell |
485,358
-386,856
| -44% | -$2.14M | ﹤0.01% | 4860 |
|
|
2023
Q1 | $4.97M | Buy |
872,214
+835,597
| +2,282% | +$5.04M | ﹤0.01% | 3481 |
|
|
2022
Q4 | $369K | Sell |
36,617
-89,625
| -71% | -$1.68M | ﹤0.01% | 8606 |
|
|
2022
Q3 | $2.83M | Buy |
126,242
+9,890
| +9% | +$286K | ﹤0.01% | 4199 |
|
|
2022
Q2 | $2.88M | Buy |
116,352
+61,539
| +112% | +$1.7M | ﹤0.01% | 4153 |
|
|
2022
Q1 | $2.13M | Sell |
54,813
-51,390
| -48% | -$1.99M | ﹤0.01% | 5344 |
|
|
2021
Q4 | $6.21M | Buy |
106,203
+19,989
| +23% | +$1.13M | ﹤0.01% | 3392 |
|
|
2021
Q3 | $5.11M | Buy |
86,214
+53,206
| +161% | +$4.17M | ﹤0.01% | 3920 |
|
|
2021
Q2 | $2.87M | Sell |
33,008
-9,149
| -22% | -$737K | ﹤0.01% | 5125 |
|
|
2021
Q1 | $3.48M | Sell |
42,157
-28,622
| -40% | -$2.74M | ﹤0.01% | 4651 |
|
|
2020
Q4 | $6.44M | Sell |
70,779
-62,505
| -47% | -$3.88M | ﹤0.01% | 3045 |
|
|
2020
Q3 | $5.33M | Buy |
133,284
+22,005
| +20% | +$768K | ﹤0.01% | 2968 |
|
|
2020
Q2 | $3.82M | Buy |
111,279
+75,969
| +215% | +$2.26M | ﹤0.01% | 3400 |
|
|
2020
Q1 | $784K | Sell |
35,310
-60,347
| -63% | -$1.53M | ﹤0.01% | 5931 |
|
|
2019
Q4 | $1.87M | Buy |
95,657
+21,023
| +28% | +$334K | ﹤0.01% | 4438 |
|
|
2019
Q3 | $1.16M | Buy |
74,634
+21,094
| +39% | +$404K | ﹤0.01% | 5373 |
|
|
2019
Q2 | $1.09M | Buy |
+53,540
| New | +$965K | ﹤0.01% | 5453 |
|
|
2018
Q3 | – | Sell |
-22,895
| Closed | -$271K | – | 9499 |
|
|
2018
Q2 | $260K | Sell |
22,895
-5,539
| -19% | -$61K | ﹤0.01% | 8126 |
|
|
2018
Q1 | $278K | Sell |
28,434
-20,700
| -42% | -$198K | ﹤0.01% | 7752 |
|
|
2017
Q4 | $300K | Buy |
+49,134
| New | +$219K | ﹤0.01% | 7597 |
|
Other funds holding FATE
RG
VCM
VPM
JJ
Susquehanna International Group's FATE Position: Q1 2026 in Review
Susquehanna International Group reduced its Fate Therapeutics (FATE) stake by 3.8% in Q1 2026, selling an estimated $14.2K and leaving 298,496 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #10473.
Susquehanna International Group first reported a position in FATE in Q4 2017 and has held it in 31 quarters since. The position peaked at $6.44M in Q4 2020. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.
- Susquehanna International Group held 298,496 shares of Fate Therapeutics worth $358K as of Q1 2026.
- Susquehanna International Group sold 11,695 Fate Therapeutics shares in Q1 2026, an estimated $14.2K.
- Fate Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10473 holding.
- Susquehanna International Group first reported a position in Fate Therapeutics in Q4 2017 and has held it in 31 quarters since.
- Susquehanna International Group's Fate Therapeutics position peaked at $6.44M in Q4 2020.
- 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.